Allena Pharmaceuticals Inc expected to post a loss of 16  cents a share - Earnings Preview

Allena Pharmaceuticals

04/03/2022 11:28

* Allena Pharmaceuticals Inc  ALNA.OQ   ALNA.O  is expected
to show no change in quarterly revenue when it reports 
results on March 7 (estimated). 
    * ​Refinitiv's mean analyst estimate for Allena
Pharmaceuticals
Inc is for a loss of 16 cents per share. For the same quarter
last year, the company reported a loss of 24 cents per share.
    * The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Allena
Pharmaceuticals Inc is $3.5​, about 84.6% above​ its last
closing price of $0.54. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Sep. 30 2021  -0.19       -0.18      -0.17     Beat    8.1
 Jun. 30 2021  -0.21       -0.21      -0.24     Missed  -14.3
 Mar. 31 2021  -0.22       -0.23      -0.21     Beat    7.7​
 Dec. 31 2020  -0.19       -0.19      -0.24     Missed  -24.4
 ​​Sep.        -0.21       -0.21      -0.22     Missed  -3.4
 30 2020                                                
 Jun. 30 2020  -0.27       -0.30      -0.26     Beat    13.2​
 Mar. 31 2020  -0.43       -0.45      -0.31     Beat    31.1
 Dec. 31 2019  -0.54       -0.53      -0.47     Beat    11.6
 This summary was machine generated March 4 at 11:28 GMT.  All
figures in US dollars  unless otherwise stated